Clostridium Spore Compositions for Regulatory T Cell Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms of how regulatory T cells (Treg cells) are induced in the colon and produce IL-10 at a high level are unclear, and the influence of intestinal commensal bacteria on their induction is not well understood, which hinders effective treatments for autoimmune diseases and inflammatory bowel disease.
Innovation Solution
The use of chloroform-treated fractions and spore-forming bacteria from the genus Clostridium, or their active substances, is found to induce the proliferation and accumulation of regulatory T cells, which suppress effector T cell proliferation and regulate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the mechanisms of regulatory T cell induction and IL-10 production are not understood, then effective treatments for autoimmune diseases cannot be developed, but researching these mechanisms requires complex experimental systems and time-consuming studies
Solution Approach 1:
The patent extracts the active ingredient (bacteria or bacterial product) from the complex intestinal microbiota and presents it in isolation. This allows the specific mechanism of Treg cell induction to be studied without the confounding variables of other bacteria present in the gut, thereby accelerating the research timeline while maintaining treatment effectiveness.
Solution Approach 2:
The patent introduces a controlled experimental model using germ-free animals or cell cultures as intermediaries between the bacteria and the immune system. This intermediary system enables precise investigation of the bacteria-Treg cell interaction mechanism without the complexity of the full gut ecosystem, reducing research time while preserving biological relevance.
2Reliability
If intestinal commensal bacteria are not well understood, then effective treatments for autoimmune diseases cannot be developed, but studying these bacteria requires complex microbiota analysis and controlled experimental conditions
Solution Approach 1:
The patent isolates specific bacteria (Clostridium clusters IV and XIVa) or their active substances from the complex intestinal microbiota. This extraction simplifies the analysis by focusing on a single or limited set of bacterial species rather than analyzing the entire microbiota composition, thereby reducing experimental complexity while maintaining treatment efficacy.
Solution Approach 2:
The patent segments the complex microbiota into functional groups (Clostridium clusters) and further into specific strains or metabolites. This segmentation allows for targeted study of specific bacterial functions related to Treg cell induction, simplifying the analytical process while preserving the biological activity needed for effective treatment.
3Reliability
If regulatory T cells are not induced, then immune suppression is insufficient for treating autoimmune diseases, but inducing Treg cells requires specific bacterial strains or metabolites that are difficult to obtain and standardize
Solution Approach 1:
The patent identifies and standardizes specific parameters of the bacteria (such as Clostridium clusters IV and XIVa) or their metabolites that are critical for Treg cell induction. By focusing on these specific parameters rather than using undefined microbial mixtures, the patent achieves reliable immune suppression while improving manufacturability through standardized cultivation and purification protocols.
Solution Approach 2:
The patent utilizes bacterial spores or defined microbial strains that can be easily cultured, stored, and standardized. These standardized preparations can be produced at scale with consistent quality, making them suitable for clinical application. The use of defined strains replaces complex, non-standardizable microbiota preparations, thereby improving ease of manufacture while maintaining therapeutic effectiveness.
Data Source
AI summary
It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.